Large study checks safety of rituximab pfizer in lymphoma patients

This study looked at medical records from over 2,700 people in Japan with a type of lymphoma (B-cell non-Hodgkin's lymphoma) who were treated with Rituximab Pfizer. The goal was to see how often infections and other side effects happened, and to compare these results with those from patients who took a similar drug called Rituxan. The study did not test a new treatment but gathered information to better understand the safety of Rituximab Pfizer in real-world use.